Is iPSC-derived motor neuron precursor therapy for ALS available in China?

Yes. It is licensed for domestic pilot use in Hainan and is offered at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital. This pilot authorization is not nationwide approval.

Who may qualify for iPSC-derived motor neuron precursor therapy for ALS?

Adults aged 18–65 with a clinically confirmed sporadic or familial ALS diagnosis may be considered if they are in an early-to-mid disease stage and can tolerate cell transplantation. Final eligibility requires medical assessment.

Can international patients access this ALS therapy in China?

International patients can explore the treatment pathway through medical assessment and hospital coordination, subject to the hospital's eligibility and access requirements.

top of page

ChinaCurelink
a MedeboundHEALTH Company

FREE CONSULTATION

iPSC-Derived Motor Neuron Precursor Therapy for ALS Stem Cell Therapy China: 2026 International Patient Guide

ChinaCureLink

Mon Aug 31 2026

6 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page